Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients
Authors
Djebbari, FaouziRampotas, Alexandros
Vallance, Grant
Panitsas, Fotios
Basker, Nanda
Sangha, Gina
Salhan, Beena
Karim, Farheen
Al-Kaisi, Firas
Gudger, Amy
Ngu, Loretta
Poynton, Matt
Lam, Ho Pui Jeff
Morgan, Lowri
Yang, Laura
Young, Jennifer
Walker, Mairi
Tsagkaraki, Ismini
Anderson, Laura
Chauhan, Saleena Rani
Maddams, Rebecca
Soutar, Richard
Triantafillou, Margarita
Prideaux, Steve
Obeidalla, Abubaker
Eyre, Toby A
Bygrave, Ceri
Kothari, Jaimal
Basu, Supratik

Ramasamy, Karthik
Issue Date
2023-01-31
Metadata
Show full item recordCitation
Djebbari, F., Rampotas, A., Vallance, G. et al. (2023) Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients. British Journal of Haematology. https://doi.org/10.1111/bjh.18672Publisher
WileyJournal
British Journal of HaematologyPubMed ID
36720464 (pubmed)Additional Links
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18672Type
Journal articleLanguage
enDescription
This is an accepted manuscript of an article published by Wiley on 31/01/2023, available online: https://doi.org/10.1111/bjh.18672 The accepted version of the publication may differ from the final published version.ISSN
0007-1048EISSN
1365-2141ae974a485f413a2113503eed53cd6c53
10.1111/bjh.18672
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/
Related articles
- Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
- Authors: Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Kothari J, Basu S, Ramasamy K
- Issue date: 2023 Jan 31
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
- Authors: Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC, ICARIA-MM study group
- Issue date: 2019 Dec 7
- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
- Authors: Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG
- Issue date: 2021 May
- Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
- Authors: Harrison SJ, Perrot A, Alegre A, Simpson D, Wang MC, Spencer A, Delimpasi S, Hulin C, Sunami K, Facon T, Vlummens P, Yong K, Campana F, Inchauspé M, Macé S, Risse ML, van de Velde H, Richardson P
- Issue date: 2021 Jul